Gland Pharma has announced the execution of a strategic Manufacturing and Supply Agreement (MSA) with one of the leading global pharmaceutical companies for technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets.

The partnership establishes Gland Pharma as an integrated end-to-end partner supporting multiple products across various stages of the product lifecycle, including both commercially marketed products and pipeline products under development. The collaboration follows a full-service CDMO model encompassing technology transfer, process development, scale-up, validation, commercial manufacturing, and long-term supply of sterile injectable products.

The portfolio comprises a diversified basket of oncology and non-oncology products in Vial, Lyo, Ampoules and Pre-Filled Syringe (PFS) presentations, covering both complex and conventional injectable formulations.

Under the agreement, Gland Pharma will leverage its integrated capabilities across development, technology transfer, manufacturing, quality and regulatory support to provide a comprehensive "one-stop" solution to its partner.

The agreement is expected to provide strong long-term business visibility, with revenue generation anticipated from calendar year 2029. The current agreement covers 55 SKUs to be manufactured across 3 sites, with scope of adding more products soon. Once all products are commercialised, the annualised revenue potential is expected to be approximately USD 90-100 million.

Technology transfer activities are planned for completion within 2 years, with revenues expected to commence from calendar year 2029.

The partnership represents an important milestone in Gland Pharma's growth journey and further strengthens its position as a trusted global CDMO partner for pharmaceutical companies seeking a full-service model including integrated development, technology transfer and manufacturing solutions for sterile injectable products.

Srinivas Sadu, Executive Chairman, Gland Pharma, said, “We are pleased to enter into this strategic collaboration. The partnership highlights the confidence global pharmaceutical companies place in Gland Pharma's development, technology transfer, manufacturing, and supply capabilities. The agreement provides meaningful long-term revenue visibility, supports expansion of our CDMO business, and creates a strong foundation for future growth. We remain committed to investing in the capabilities and capacity required to support our partner's evolving needs and ensure reliable supply to patients worldwide.”